Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-12-09 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
We have been intimated by our Registrar and Share Transfer Agent that their name has changed from "KARVY FINTECH PRIVATE LIMITED" to "KFIN TECHNOLOGIES PRIVATE LIMITED" w.e.f. 5th December 2019. ....
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 176 characters, which is extremely short and contains no report content. It does not contain any financial statements, regulatory information, or announcements. Given the lack of content, this document cannot be classified as a report or detailed filing. It is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2019-12-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 60% confidence The document consists of a brief table listing dates, fund/investor names, venues, and types of meetings, including calls and in-person meetings. There is no detailed financial data, no report content, no regulatory or legal information, and no announcements of voting results or management changes. The document appears to be a schedule or record of investor meetings or calls, which aligns most closely with a Call Transcript (CT) category, as it relates to company conference calls or investor meetings. However, since the document does not contain a full transcript but only a schedule of calls, it is not a full call transcript. Given the limited content and the nature of the document, the best fit is Call Transcript (CT) as it relates to calls and meetings with investors, albeit minimal. Confidence is moderate due to limited content.
2019-12-06 English
Please find enclosed schedule of analyst / investor meetings of the Company
Call Transcript Classification · 60% confidence The document contains a table listing dates, fund/investor names, venues, and types of meetings, including a 'Call' type meeting. The content is brief and appears to be a schedule or record of meetings rather than a detailed report or announcement. There is no financial data, regulatory references, or report titles. The document length is very short (344 characters), indicating it is not a full report. This fits best with a Call Transcript (CT) or possibly a meeting schedule related to calls. However, since it lists a 'Call' type meeting and other meeting types without transcript content, it is more likely a schedule or summary related to calls rather than a full transcript. Given the options, the closest classification is Call Transcript (CT) as it relates to company calls, but the document is more of a meeting schedule. Since no other category fits better and it relates to calls, CT is the best fit with moderate confidence.
2019-12-06 English
Related Party Transactions
Interim / Quarterly Report Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended 30th September 2019, as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed financial data on remuneration, testing charges, contributions, donations, rent, reimbursements, investments, payables, and dividends related to key management personnel and related parties. The document is substantive and includes actual financial figures for the half year period, indicating it is a financial disclosure report rather than a mere announcement or certification. The content aligns with regulatory requirements for related party transaction disclosures, which are typically part of interim or quarterly financial reporting. Therefore, the document fits best under the category of Interim / Quarterly Report (IR), as it provides comprehensive financial data for a period shorter than a full fiscal year and is not just a summary or announcement.
2019-12-03 English
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of related party transactions on a consolidated ....
Interim / Quarterly Report Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended 30th September 2019, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed financial data on remuneration, contributions, donations, investments, and payables related to key management personnel and related parties. The presence of substantive financial data for a half-year period indicates this is a financial report rather than a mere announcement. The document is not a full annual report but a half-year disclosure with financial details, fitting the definition of an Interim / Quarterly Report (IR).
2019-12-03 English
Please find enclosed schedule of analyst / investor meetings of the Company
Regulatory Filings Classification · 95% confidence The document is a short notice regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is an announcement of upcoming meetings rather than a detailed financial report, earnings release, or presentation. It does not contain financial data, management discussion, or detailed investor presentation materials. Given the nature of the document as a schedule/intimation of meetings with investors, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is short (1494 characters), and it is not a report or presentation itself.
2019-11-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.